The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers

Title
The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers
Authors
Keywords
Rhenium(I)-diselenoether, Rhenium, Selenium, Cancer, Selectivity, ROS, VEGF, IGF, TGF
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-11
DOI
10.1007/s10637-019-00727-1

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started